Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA)

Historical Holders from Q1 2016 to Q3 2025

Symbol
NTLA on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
108M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
104M
Holdings value
$1.8B
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
276
Number of buys
144
Number of sells
-114
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 11.1% $206M 11.9M ARK Investment Management LLC 30 Sep 2025
VANGUARD GROUP INC 10% $84.7M 10.2M The Vanguard Group 31 Dec 2024
BlackRock, Inc. 8.2% $70.2M 8.45M BlackRock, Inc. 31 Mar 2025
Contrarius Investment Management Ltd 5.5% $102M 5.89M Contrarius Investment Management Ltd 30 Sep 2025
GOLDMAN SACHS GROUP INC 5.1% $95M 5.5M THE GOLDMAN SACHS GROUP, INC. 30 Sep 2025
STATE STREET CORP 4.4% $37.5M 4.51M STATE STREET CORPORATION 31 Mar 2025

Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 104M $1.8B +$104M $17.27 276
2025 Q2 99.5M $934M -$6.83M $9.38 277
2025 Q1 101M $720M +$1.66M $7.11 289
2024 Q4 99.2M $1.16B -$49.3M $11.66 288
2024 Q3 93.2M $1.91B +$52.7M $20.55 277
2024 Q2 90.1M $2.02B -$33.1M $22.38 286
2024 Q1 91M $2.5B +$159M $27.51 279
2023 Q4 85.3M $2.6B +$154M $30.49 289
2023 Q3 80.2M $2.53B +$57.6M $31.62 281
2023 Q2 78.3M $3.19B -$9.43M $40.78 288
2023 Q1 78.7M $2.93B +$27.2M $37.27 288
2022 Q4 78.1M $2.72B +$325M $34.89 294
2022 Q3 68.1M $3.81B -$6.96M $55.96 308
2022 Q2 67.6M $3.44B +$98.1M $51.76 282
2022 Q1 65.2M $4.72B -$27.3M $72.67 341
2021 Q4 64.2M $7.59B +$201M $118.24 361
2021 Q3 62.2M $8.34B +$38.2M $134.15 354
2021 Q2 61.9M $10B +$39.1M $161.91 329
2021 Q1 63M $5.06B +$268M $80.25 255
2020 Q4 61.9M $3.36B +$188M $54.40 239
2020 Q3 56.5M $1.13B +$49.6M $19.88 161
2020 Q2 53.9M $1.13B +$161M $21.02 160
2020 Q1 46.4M $568M +$9.02M $12.23 133
2019 Q4 45.6M $669M +$24.4M $14.67 137
2019 Q3 44.1M $589M +$69.2M $13.35 131
2019 Q2 38.8M $635M +$86.6M $16.37 142
2019 Q1 33.5M $570M +$44.5M $17.08 142
2018 Q4 31.5M $430M +$12.1M $13.65 136
2018 Q3 29.1M $833M +$7.44M $28.62 149
2018 Q2 28.9M $789M +$71.3M $27.36 151
2018 Q1 26.4M $557M +$49.3M $21.09 127
2017 Q4 24.3M $467M +$127M $19.22 110
2017 Q3 17.7M $439M +$20.7M $24.85 84
2017 Q2 16.8M $269M +$2.83M $16.00 81
2017 Q1 16.7M $236M -$10.7M $14.09 73
2016 Q4 18.4M $241M -$6.13M $13.11 67
2016 Q3 14.3M $243M +$573K $17.02 64
2016 Q2 14.1M $300M +$298M $21.35 61
2016 Q1 215 $4K $18.60 1